---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-25-002140"
form_type: "8-K"
ticker: "CNSP"
cik: "0001729427"
company_name: "CNS Pharmaceuticals, Inc."
filed_at: "2025-03-31T23:59:59+00:00"
generated_at: "2026-05-24T01:59:24.831473+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# CNS Pharmaceuticals regains Nasdaq compliance; subject to one-year monitoring period

## Summary
- Nasdaq letter dated March 31, 2025 confirms regained compliance with $1.00 bid price rule.
- Company subject to Mandatory Panel Monitor for one year from letter date.
- If noncompliance occurs within monitoring period, no additional cure period allowed; delisting process begins.
- Previous reverse stock splits (>250:1 cumulative) disqualified company from standard compliance period.

## SEC filing metadata
- accession: 0001683168-25-002140
- form_type: 8-K
- ticker: CNSP
- cik: 0001729427
- company_name: CNS Pharmaceuticals, Inc.
- filed_at: 2025-03-31T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1729427/000168316825002140/0001683168-25-002140-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1729427/000168316825002140/cns_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-25-002140
- JSON: https://secwatch.observer/filing/0001683168-25-002140.json
- Plain text: https://secwatch.observer/filing/0001683168-25-002140.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.